Breakthrough trial offers hope for patients stuck on kidney transplant waitlists
NCT ID NCT04827979
Summary
This study is testing whether two existing drugs, daratumumab and belatacept, can help kidney transplant patients who are 'highly sensitized'—meaning their immune systems attack most donor kidneys. The treatment aims to lower these harmful antibodies, making it easier to find a compatible donor and get a transplant sooner. The trial involves 19 adults on dialysis who have been waiting a very long time for a match, and it will check if the approach is safe and effective.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGHLY SENSITIZED PROSPECTIVE KIDNEY TRANSPLANT RECIPIENTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California at San Francisco Medical Center
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.